Correction to: Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine.

Kazmi, Shayma; Chatterjee, Debanjana; Raju, Dheeraj; Hauser, Rob; Kaufman, Peter A

Kazmi, Shayma; Chatterjee, Debanjana; Raju, Dheeraj; Hauser, Rob; Kaufman, Peter A.

Afiliação

Kazmi S; Cancer Treatment Centers of America, Philadelphia, PA, USA. shayma.kazmi@ctca-hope.com.
Chatterjee D; US Health Economics Outcomes Research and Real World Evidence, Eisai Inc., Woodcliff Lake, NJ, USA.
Raju D; Cancer Treatment Centers of America Global, Inc., Boca Raton, FL, USA.
Hauser R; Cancer Treatment Centers of America Global, Inc., Boca Raton, FL, USA.
Kaufman PA; Larner College of Medicine, Division of Hematology/Oncology, University of Vermont Cancer Center, Burlington, VT, USA. peter.kaufman@uvmhealth.org.

Breast Cancer Res Treat ; 187(2): 603, 2021 Jun.

Article em En | MEDLINE | ID: mdl-33907908

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article